Keywords :
Animals; Antineoplastic Agents/administration & dosage/therapeutic use; Cat Diseases/drug therapy; Cats; Cyclophosphamide/administration & dosage/therapeutic use; Female; Injections, Intraperitoneal; Lymphoma/drug therapy/veterinary; Male; Prednisolone/administration & dosage/therapeutic use; Vincristine/administration & dosage/therapeutic use; cat; chemotherapy; intraperitoneal; lymphoma; safety
Abstract :
[en] In this retrospective study, the efficacy and safety were examined for an intraperitoneal chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with malignant lymphoma. Certainly in cats fiercely resisting IV administration the IP route is a more practical method, safer for the administrator and less stressful for the cat. Complete remission (CR) rate was 76.9% (n = 20). Median duration of first remission was 421 days. Estimated 1- and 2-year disease free period were 67.1 and 48.0%, respectively. Median duration of survival was 388 days and estimated overall 1- and 2-year survival periods were 54.7 and 46.9% respectively. Young cats had a more favourable prognosis. Reaching CR was essential for long-term survival. No specific IP-related adverse events (AE) were seen. AE were generally scored as mild and were not excessively abundant. These results indicate that the IP route is a safe and effective alternative for the administration of COP protocol chemotherapeutics.
Scopus citations®
without self-citations
8